GLSI Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. (GLSI) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.34 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.9% since its last earnings release on August 11, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences Inc. is a clinical stage biopharmaceutical company focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor. The company's product candidate includes GP2, which is in clinical stage. Greenwich LifeSciences Inc.is based in Stafford, Texas.
Sector
Healthcare
Industry
Biotechnology